je.st
news
Tag: disease
New Report on Animal Disease Status in Indian Ocean States
2013-06-13 02:00:00| ThePigSite - Industry News
INDIAN OCEAN STATES - To mark the first International forum on Public Health Surveillance and Response in island territories, held in St Denis, Réunion, from 11 to 13 June 2013, Eric Cardinale, a researcher with CIRAD, reports on five years of surveillance and research within the AnimalRisk animal health network he heads in the Indian Ocean.
Tags: report
states
status
animal
AHVLA: PCV2-associated Disease on Newly-established Unit
2013-06-12 02:00:00| ThePigSite - Industry News
UK - Intestinal torsion on an outdoor unit, outbreaks of Glässers disease in the early post-weaning period and porcine circovirus-2-associated disease on a newly-established unit have been noted in the AHVLA's pig disease surveillance for March 2013.
Waste Food Campaign Poses Disease Threat
2013-06-10 02:00:00| ThePigSite - Industry News
UK - The National Pig Association has warned that recycling human food by feeding it to pigs must take place only under strictly-controlled conditions, otherwise there is a risk of outbreaks of notifiable diseases, such as foot-and-mouth, classical swine fever and African swine fever.
Tags: food
disease
waste
campaign
Man with kidney disease first in U.S. to get bioengineered vein
2013-06-07 03:00:07| CNET News.com
In a first-of-its kind procedure, surgeons implant the blood vessel into the arm of a 62-year-old Virginia man with renal failure. [Read more]
Merck Provides Update on Phase III Clinical Program for Preladenant, the Companys Investigational Parkinsons Disease Medicine
2013-05-23 23:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Mercks investigational adenosine A2A receptor antagonist for the treatment of Parkinsons disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladenant compared with placebo. Language: English Contact HTML: MerckMedia Contacts:Pam Eisele, 908-423-5042orClaire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: program
iii
update
medicine
Sites : [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] next »